Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antitumour metallocenes: structure-activity studies and interactions with biomolecules.

M M Harding1, G Mokdsi

  • 1School of Chemistry, University of Sydney, N.S.W., New South Wales, 2006, Australia. harding@chem.usyd.edu.au

Current Medicinal Chemistry
|October 18, 2000
PubMed
Summary

Metallocene dihalides show anticancer promise by forming DNA complexes, but their exact active species and in vivo mechanisms remain unclear. Research is ongoing to identify these active components and understand their interactions with cellular targets.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antitumour Metallocenes: Effect of DMSO on the Stability of Cp(2)TiX(2) and Implications for Anticancer Activity.

Metal-based drugs·2008
Same author

The role of ring D in the antitumour antibiotic streptonigrin: metal complexation, DNA binding and topoisomerase inhibition by ABC ring analogues of streptonigrin.

Anti-cancer drug design·2002
Same author

A (1)H NMR study of the interaction of antitumor metallocenes with glutathione.

Journal of inorganic biochemistry·2001
Same author

Inhibition of human topoisomerase II by the antitumor metallocenes.

Journal of inorganic biochemistry·2001
Same author

Hydrophobic analogues of the winter flounder 'antifreeze' protein.

FEBS letters·2001
Same author

Geometry of metal-ligand interactions in proteins.

Acta crystallographica. Section D, Biological crystallography·2001

Area of Science:

  • Organometallic Chemistry
  • Medicinal Chemistry
  • Cancer Biology

Background:

  • Metallocene dihalides are novel hydrophobic organometallic compounds with demonstrated antitumor activity across various cell lines and tumor models.
  • Titanocene dichloride is the most studied metallocene and is currently in Phase II clinical trials.
  • While DNA complex formation is implicated, the precise active species and molecular mechanisms of action for metallocene anticancer agents in vivo are not fully elucidated, unlike platinum-based drugs.

Purpose of the Study:

  • To identify the biologically active species of metallocene dihalides.
  • To elucidate the molecular-level mechanism of action of metallocene dihalides in vivo.
  • To explore interactions with biomolecular targets and potential cellular transport mechanisms.

Main Methods:

Related Experiment Videos

  • Review of recent studies investigating metallocene dihalides.
  • Studies involving interactions with nucleotides, oligonucleotides, DNA, and proteins (topoisomerases, protein kinase C, transferrin).
  • Structure-activity relationship studies, including design of hydrolytically stable metallocenes and water-soluble analogues.

Main Results:

  • Metallocenes inhibit DNA and RNA synthesis, with titanium and vanadium accumulating in nucleic acid-rich tumor regions.
  • Studies with biomolecules provided insights into cellular transport and target interactions.
  • Despite efforts in structure modification, improved anticancer activity for titanocene dichloride was not achieved, highlighting unique mechanisms for each metallocene.

Conclusions:

  • The exact in vivo active species and mechanisms of metallocene dihalides remain to be fully identified.
  • The distinct chemical and hydrolytic stability of each metallocene suggests unique in vivo mechanisms of action.
  • Further research is needed to fully understand and optimize these promising anticancer agents.